All the news Showing 10 of 93 articles from: HCV and coinfectionsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Co-infection with HCV increases cancer risk for people with HIV Michael Carter / 28 March 2017 People with HIV and hepatitis C virus (HCV) co-infection have an increased risk of non-AIDS-defining cancers compared to people with HIV mono-infection, investigators from Spain report in the online edition of AIDS. Even ... Two-thirds of people with HIV/HCV co-infection in Southeast Asia in need of HCV therapy Michael Carter / 15 March 2017 Almost two-thirds of people with HIV/hepatitis C virus (HCV) co-infection in Asia are in need of HCV therapy with a fifth of people having cirrhosis, investigators report in the Journal of Viral ... Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals Liz Highleyman / 13 March 2017 AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for people with HIV/hepatitis C ... DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants Liz Highleyman / 07 March 2017 People with HIV/hepatitis C virus (HCV) co-infection with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for ... Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... New hepatitis C infections among HIV-positive gay men drop by half after direct-acting antiviral roll-out in Netherlands Liz Highleyman / 17 February 2017 A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals for the treatment of hepatitis C, researchers have already seen a dramatic decline in acute ... High hepatitis C prevalence seen in Amsterdam PrEP study participants Gus Cairns / 06 February 2017 Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline.The HCV ... European Medicines Agency warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C EMA / 07 December 2016 HCV Drugs May Reactivate HBV, FDA Warns Medscape (free registration required) / 06 October 2016 Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive people with viral hepatitis Michael Carter / 01 September 2016 Incidence of endstage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the United States ... ← Prev1...23456...10Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive